Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma
Clinical trial NCT07094477 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07094477
- Sponsor
- Daihong Liu
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-01
- Primary completion
- 2027-03-31
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.